Last updated: April 26, 2026
Who supplies fulvestrant for pharmaceutical manufacturing?
Fulvestrant (INN) is a high-value injectable endocrine therapy. The supply chain spans API manufacture, peptide/sterile drug product manufacturing, and cold-chain distribution. Across the market, supplier participation falls into three lanes: (1) API manufacturers, (2) finished-dose sterile manufacturers, and (3) component and packaging suppliers used to build the injector/kit.
Which companies manufacture fulvestrant API?
Fulvestrant API supply is concentrated in a limited set of global chemical/pharma API manufacturers. The most visible public suppliers tied to fulvestrant API and/or fulvestrant intermediate work are:
| Supplier |
Likely role in fulvestrant value chain |
Evidence basis (public) |
| Dr. Reddy’s Laboratories (India) |
API and/or authorized supply for generic fulvestrant injectables |
Industry filings and regulatory activity tied to fulvestrant products for US/EU markets (company footprint in injectable oncology APIs) |
| Viatris / Former Mylan ecosystem (global) |
Sourced API and/or contract manufacturing for finished injectables |
Company market presence and generic fulvestrant portfolio footprint in multiple jurisdictions |
| Teva (Israel/Global) |
Contract manufacturing and/or sourced API for generics |
Teva’s oncology injectables footprint and supplier network for sterile injectables |
| Sandoz (global) |
Sourced API and/or CDMO-built injectables for generics |
Sandoz generic injectable oncology portfolio footprint |
| Accord / Hikma / Sandoz-style generic manufacturers (global) |
Typically finished-dose supply, using outsourced sterile manufacturing and API sourcing |
Observed pattern across generic fulvestrant labelers and sourcing practices |
Important boundary: In publicly accessible regulatory databases, “API manufacturer” is not always shown as a named entity for every product submission. The most consistent visible “supplier list” you can use for real procurement is the set of finished-dose marketing authorization holders and contract sterile manufacturers listed in regulatory dossiers and label/packaging information. Where the API is not explicitly disclosed publicly, supplier identification is done through dossier-linked corporate activity and supplier fingerprints.
Who manufactures finished-dose fulvestrant (sterile injection)?
Finished-dose fulvestrant is produced as a sterile intramuscular depot injection. Manufacturing requires sterile fill-finish, controlled particle and viscosity specifications, and device compatibility with prefilled syringes or prefilled injection systems (depending on brand and jurisdiction).
The finished-dose manufacturer/sponsor landscape is typically dominated by:
- Originator labeler for branded products (historically: AstraZeneca for Faslodex in many markets)
- Generic labelers that source API and contract sterile fill-finish with CDMOs
Branded fulvestrant
| Brand |
Labeler (typical originator) |
Common finished product ownership |
| Faslodex |
AstraZeneca |
Originator finished-dose supply and lifecycle management |
AstraZeneca’s Faslodex is the primary branded fulvestrant reference product used for regulatory comparability. [1]
Generic fulvestrant injectables
| Category |
Typical participant structure |
Procurement relevance |
| Generic marketing authorization holder (MAH) |
Brand- or MAH-branded product sold under national/regional approvals |
Defines “supplier” on invoices and release documents |
| Contract manufacturer (CDMO) |
Sterile manufacturing and fill-finish under contract |
Determines actual batch-making site, quality unit processes, and lead times |
Publicly, generic fulvestrant approvals exist across multiple jurisdictions (EU via national approvals and centralized routes for certain MAH portfolios; US via ANDA pathway). The “supplier” you can contract with in practice is the MAH / product distributor, while the plant is the CDMO sterile manufacturer.
What supplier roles matter for sourcing fulvestrant (practical procurement map)?
To avoid mismatches between “API suppliers” and “clinical/market-ready supply,” procurement teams typically segment suppliers by deliverable:
-
API vendor
- Provides fulvestrant API with CoA, impurity profile, and regulatory documentation.
- Key specs: assay, water content/solvent residues, specified impurities, polymorphic behavior if relevant.
-
Drug product vendor (sterile fill-finish / finished injectable)
- Builds sterile fulvestrant in final presentation (single-dose/pre-filled formats).
- Key specs: sterility assurance, endotoxin limits, particulate monitoring, container closure integrity, viscosity and depot performance.
-
Device and primary packaging supplier
- Supplies syringe, needle, plunger, stopper/closure components, and sometimes assembled injection systems.
- Key specs: extractables/leachables compatibility, compatibility with solution system, visual inspection standards.
Where does fulvestrant supply risk concentrate?
Fulvestrant is sensitive to:
- Sterile fill-finish capacity (not just API chemistry)
- Cold chain and logistics for injectables in certain presentations
- Regulatory batch-release capacity at the finished-dose manufacturing site
In practice, shortages often propagate from sterile manufacturing constraints and regulatory release timing, not from the synthesis step alone.
How to interpret “supplier” when evaluating fulvestrant availability
For investment and R&D planning, the actionable “supplier list” is not the chemical manufacturer name alone. It is the set of:
- Marketing authorization holders (what you buy)
- Manufacturing sites (where it is made)
- Unit operation constraints (sterile fill-finish, depot formulation, device compatibility)
This is the supply structure used in public regulatory processes and typical procurement contracts for injectable oncology products.
Key takeaways
- Fulvestrant supply is dominated by sterile drug product manufacturing capacity, with API sourcing flowing through a small set of established chemical/API suppliers and intermediates providers.
- The most procurement-relevant “supplier set” is the finished-dose marketing authorization holder and their listed manufacturing sites, not only API manufacturers.
- Branded supply is anchored by AstraZeneca’s Faslodex. [1]
- Generic fulvestrant supply is delivered through MAHs and contracted sterile CDMOs, using sourced API and device-compatible packaging.
FAQs
1) Who is the originator supplier for fulvestrant?
AstraZeneca is the originator labeler for Faslodex in major markets. [1]
2) Are fulvestrant API suppliers the same as finished-dose manufacturers?
Not typically. API is commonly sourced by MAHs, while finished-dose sterile injectables are produced by specific CDMO sites under contract or within the MAH network.
3) What is the most critical bottleneck in fulvestrant supply?
Sterile fill-finish and regulatory batch-release capacity for the finished injectable.
4) How do generic companies supply fulvestrant?
Generic MAHs typically procure fulvestrant API and commission or contract sterile manufacturing for the final injectable presentation.
5) What should procurement teams prioritize when selecting a fulvestrant supplier?
The manufacturing site listed on regulatory documentation, batch-release controls, sterility/endotoxin compliance record, and logistics for the finished product presentation.
References
[1] AstraZeneca. Faslodex (fulvestrant) product information and labeling (public product documentation).
